## CLAIMS

1. Use of a TACI-Fc fusion protein in the manufacture of a medicament for treating IgA nephropathy, wherein the TACI-Fc fusion protein comprises an amino acid sequence set forth in SEQ ID NO: 4, and wherein the TACI-Fc fusion protein is to be administered at a dose ranging from 160 to 240 mg.

2. The use according to claim 1, wherein the TACI-Fc fusion protein is telitacicept.

3. The use according to claim 1 or 2, wherein the TACI-Fc fusion protein is to be administered at a dose of 160 mg or 240 mg each time.

4. The use according to any one of claims 1-3, wherein the TACI-Fc fusion protein is to be administered at a dose of 160 mg or 240 mg once weekly.

5. The use according to any one of claims 1-4, wherein the TACI-Fc fusion protein is to be administered 2-4 times per month and/or to be administered continuously for 2-50 weeks.

6. The use according to any one of claims 1-5, wherein the TACI-Fc fusion protein is to be administered by subcutaneous injection, intramuscular injection, oral or intravenous administration.

7. The use according to any one of claims 1-6, wherein the IgA nephropathy is primary IgA nephropathy.

8. The use according to any one of claims 1-7, wherein the TACI-Fc fusion protein is in a pharmaceutical composition, and wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.